The federal government has awarded Novo Nordisk Inc., a global healthcare company, an Indefinite Delivery Contract (IDC) worth up to $470,487,013.27 to supply various types of human insulin. The single-award IDC was issued by the Department of Veterans Affairs' (VA) National Acquisition Center and has a period of performance from July 1, 2020 to June 30, 2025, with a one-year base period and four one-year option periods.
The IDC aims to ensure an uninterrupted, cost-effective supply of critical insulin medications for federal health programs, including the VA, Department of Defense, Bureau of Prisons, and Indian Health Service. The contract covers a range of insulin products in vial and disposable pen packaging, including Human R, Human N, Human 70/30, short-acting/intermediate analog mixes, and short-acting analog insulins. The total estimated annual requirements across the two product groups exceed 5 million units. Novo Nordisk, as the prime contractor, will leverage its manufacturing capabilities to fulfill task orders placed under the IDC for distribution to federal hospitals, clinics, and other healthcare facilities.
Generated 1/11/25, 9:05 AM